ERBB2 and breast cancer: The novel taxonomy of breast cancer into four molecularly distinct subtypes has proven critical in the personalisation of therapeutics [2] and patients with tumours expressing HER2 signalling have proven to be the main beneficiaries following the revolutionary advent of Trastuzumab [25].